# Kirsten van Nimwegen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kirsten-van-nimwegen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 82 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 2 |
| i10-index | 1 |
| Last Known Institution | Becton Dickinson (Netherlands) |
| OpenAlex ID | https://openalex.org/A5008228831 |
| Works | 7 |

## Researcher papers

- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK](https://scholariq.org/papers/p944-real-world-patient-characteristics-and-survival-outcomes-of-lenalidomide/)
- [P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA](https://scholariq.org/papers/p979-patient-reported-outcomes-for-teclistamab-versus-real-world-physician-s/)
- [P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison](https://scholariq.org/papers/p-244-teclistamab-versus-belgian-real-world-clinical-practice-in-triple-class/)
- [Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis](https://scholariq.org/papers/inpatient-vs-outpatient-treatment-management-with-teclistamab-in-relapsed-and/)
- [Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries](https://scholariq.org/papers/health-loss-due-to-market-access-delays-and-reimbursement-restrictions-in-first/)
- [PCN44 - FIRST-LINE TREATMENT EFFICACY IN EGFR-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS](https://scholariq.org/papers/pcn44-first-line-treatment-efficacy-in-egfr-positive-non-small-cell-lung-cancer/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Researcher university

- [Becton Dickinson (Netherlands)](https://scholariq.org/institutions/becton-dickinson-netherlands/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.